PureTech Health plc (PTCHF)
USD 1.75
(-5.91%)
USD 1.75
(-5.91%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 144.59 Million USD | -27.66% |
| 2022 | 199.89 Million USD | 24.73% |
| 2021 | 160.26 Million USD | 25.33% |
| 2020 | 127.87 Million USD | -11.25% |
| 2019 | 144.08 Million USD | 19.68% |
| 2018 | 120.39 Million USD | 3.72% |
| 2017 | 116.07 Million USD | 48.12% |
| 2016 | 78.36 Million USD | 41.49% |
| 2015 | 55.38 Million USD | 184.64% |
| 2014 | 19.45 Million USD | 92.57% |
| 2013 | 10.1 Million USD | -27.7% |
| 2012 | 13.97 Million USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 13.87 Million USD | 0.0% |
| 2024 Q1 | 13.87 Million USD | -79.53% |
| 2023 Q2 | 76.25 Million USD | 355.09% |
| 2023 Q1 | 16.75 Million USD | -84.12% |
| 2023 FY | 144.59 Million USD | -27.66% |
| 2023 Q4 | 67.8 Million USD | 552.96% |
| 2023 Q3 | 10.38 Million USD | -86.38% |
| 2022 Q4 | 105.52 Million USD | 995.66% |
| 2022 Q2 | 103.92 Million USD | 806.76% |
| 2022 Q3 | 9.63 Million USD | -90.73% |
| 2022 FY | 199.89 Million USD | 24.73% |
| 2022 Q1 | 11.46 Million USD | -87.41% |
| 2021 FY | 160.26 Million USD | 25.33% |
| 2021 Q2 | 70.26 Million USD | 181.94% |
| 2021 Q4 | 91 Million USD | 727.49% |
| 2021 Q3 | 10.99 Million USD | -84.35% |
| 2021 Q1 | 24.92 Million USD | -62.79% |
| 2020 FY | 127.87 Million USD | -11.25% |
| 2020 Q2 | 19.12 Million USD | -81.44% |
| 2020 Q3 | 98.55 Million USD | 415.31% |
| 2020 Q4 | 66.97 Million USD | -32.04% |
| 2020 Q1 | 103.03 Million USD | 52.26% |
| 2019 FY | 144.08 Million USD | 19.68% |
| 2019 Q3 | 228.52 Million USD | 218.43% |
| 2019 Q4 | 67.67 Million USD | -70.39% |
| 2019 Q2 | 71.76 Million USD | 47.68% |
| 2019 Q1 | 48.59 Million USD | 276.29% |
| 2018 Q4 | 12.91 Million USD | 0.0% |
| 2018 FY | 120.39 Million USD | 3.72% |
| 2018 Q2 | 5.59 Million USD | 0.0% |
| 2018 Q1 | 5.59 Million USD | -66.61% |
| 2018 Q3 | 12.91 Million USD | 130.91% |
| 2017 Q3 | 16.75 Million USD | 22.94% |
| 2017 Q1 | 13.62 Million USD | 2487.84% |
| 2017 Q2 | 13.62 Million USD | 0.0% |
| 2017 FY | 116.07 Million USD | 48.12% |
| 2017 Q4 | 16.75 Million USD | 0.0% |
| 2016 Q2 | 20.92 Million USD | 0.0% |
| 2016 FY | 78.36 Million USD | 41.49% |
| 2016 Q1 | 20.92 Million USD | 10.88% |
| 2016 Q4 | 526.5 Thousand USD | 0.0% |
| 2016 Q3 | 526.5 Thousand USD | -97.48% |
| 2015 Q3 | 18.86 Million USD | 43.39% |
| 2015 Q1 | 13.16 Million USD | -37.74% |
| 2015 FY | 55.38 Million USD | 184.64% |
| 2015 Q4 | 18.86 Million USD | 0.0% |
| 2015 Q2 | 13.16 Million USD | 0.0% |
| 2014 Q2 | 16.81 Million USD | 0.0% |
| 2014 Q4 | 21.13 Million USD | 0.0% |
| 2014 Q1 | 16.81 Million USD | 0.0% |
| 2014 FY | 19.45 Million USD | 92.57% |
| 2014 Q3 | 21.13 Million USD | 25.73% |
| 2013 FY | 10.1 Million USD | -27.7% |
| 2012 FY | 13.97 Million USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | 1.33 Million USD | -10727.74% |
| Arch Therapeutics, Inc. | 5.04 Million USD | -2767.825% |
| Evofem Biosciences, Inc. | 29.55 Million USD | -389.28% |
| Nascent Biotech, Inc. | 2.22 Million USD | -6384.522% |
| Rebus Holdings, Inc. | 664 Thousand USD | -21676.657% |
| Santhera Pharmaceuticals Holding AG | 37.25 Million USD | -288.121% |
| Qrons Inc. | 643.67 Thousand USD | -22364.217% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 389.56 Thousand USD | -37017.459% |
| Northwest Biotherapeutics, Inc. | 57.44 Million USD | -151.736% |
| ProtoKinetix, Incorporated | 415.47 Thousand USD | -34702.481% |
| Skye Bioscience, Inc. | 13.54 Million USD | -967.33% |
| Eiger BioPharmaceuticals, Inc. | 86.78 Million USD | -66.615% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | -2840.211% |
| Institute of Biomedical Research Corp. | 261.72 Thousand USD | -55147.473% |
| SQZ Biotechnologies Company | 85.61 Million USD | -68.884% |
| Intellipharmaceutics International Inc. | 2.91 Million USD | -4858.345% |
| Propanc Biopharma, Inc. | 1.5 Million USD | -9527.611% |
| Mesoblast Limited | 5.9 Million USD | -2349.966% |
| Marizyme, Inc. | 19.23 Million USD | -651.55% |
| Genus plc | 147.7 Million USD | 2.101% |
| VioQuest Pharmaceuticals, Inc. | 8.77 Million USD | -1547.034% |
| Pharming Group N.V. | 225.49 Million USD | 35.875% |
| Therapeutic Solutions International, Inc. | 2.04 Million USD | -6957.971% |
| CNBX Pharmaceuticals Inc. | 1.34 Million USD | -10678.394% |
| Nymox Pharmaceutical Corporation | 8.33 Million USD | -1633.985% |
| ContraFect Corporation | 56.88 Million USD | -154.174% |
| PsyBio Therapeutics Corp. | 4.4 Million USD | -3179.831% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.47 Million USD | -9678.313% |
| IMV Inc. | 37.7 Million USD | -283.453% |
| AXIM Biotechnologies, Inc. | 2.79 Million USD | -5082.025% |
| MultiCell Technologies, Inc. | 567.42 USD | -25483139.928% |
| ONE Bio Corp. | 6.44 Million USD | -2143.939% |
| Accustem Sciences Inc. | 3.74 Million USD | -3759.606% |
| RVL Pharmaceuticals plc | 85.94 Million USD | -68.244% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 531.96 Thousand USD | -27081.829% |
| Q BioMed Inc. | 3.43 Million USD | -4107.526% |
| Emmaus Life Sciences, Inc. | 24.71 Million USD | -485.058% |
| Mosaic ImmunoEngineering Inc. | 2.62 Million USD | -5403.17% |
| Biomind Labs Inc. | 994.18 Thousand USD | -14444.319% |
| American Oriental Bioengineering, Inc. | 99.33 Million USD | -45.572% |
| Provectus Biopharmaceuticals, Inc. | 1.75 Million USD | -8117.242% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 6.71 Million USD | -2052.377% |
| GlobeStar Therapeutics Corporation | 1.86 Million USD | -7655.81% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | 578488.0% |
| Acro Biomedical Co., Ltd. | 16.01 Million USD | -803.153% |
| Curative Biotechnology, Inc. | 1.83 Million USD | -7779.538% |
| GB Sciences, Inc. | 1.42 Million USD | -10079.239% |
| Alpha Cognition Inc. | 9.7 Million USD | -1389.83% |
| HST Global, Inc. | 140.9 Thousand USD | -102518.749% |
| CSL Limited | 3.44 Billion USD | 95.808% |
| Wesana Health Holdings Inc. | 1.12 Million USD | -12754.095% |
| Halberd Corporation | 74.84 Thousand USD | -193103.014% |
| Enzolytics Inc. | 2.17 Million USD | -6534.39% |
| Agentix Corp. | 1.37 Million USD | -10441.015% |
| Resverlogix Corp. | 12.71 Million USD | -1037.484% |
| Nuo Therapeutics, Inc. | 3.65 Million USD | -3860.794% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 1.53 Billion USD | 90.571% |
| Enzon Pharmaceuticals, Inc. | 1.04 Million USD | -13750.287% |
| Endonovo Therapeutics, Inc. | 2.4 Million USD | -5912.514% |
| RespireRx Pharmaceuticals Inc. | 1.57 Million USD | -9055.446% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.4 Million USD | -4146.634% |
| AVAX Technologies, Inc. | 7.31 Million USD | -1878.0% |
| Zenith Capital Corp. | 8.94 Million USD | -1516.874% |
| Genscript Biotech Corporation | 825.34 Million USD | 82.48% |
| Ember Therapeutics, Inc. | 17.42 Thousand USD | -829915.499% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.45 Million USD | -5789.138% |
| WPD Pharmaceuticals Inc. | 171.5 Thousand USD | -84208.695% |
| Cotinga Pharmaceuticals Inc. | 1.92 Million USD | -7427.542% |
| Kadimastem Ltd | 2.41 Million USD | -5899.597% |
| Helix BioMedix, Inc. | 1.97 Million USD | -7232.379% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 10.86 Million USD | -1230.606% |
| BioStem Technologies, Inc. | 22.97 Million USD | -529.372% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 181.48 Thousand USD | -79574.353% |
| LadRx Corporation | 3.81 Million USD | -3693.414% |
| Cell Source, Inc. | 4.32 Million USD | -3243.016% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | -15557.329% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | -15557.329% |
| NovAccess Global Inc. | 2.46 Million USD | -5761.816% |
| Affymax, Inc. | 39.38 Million USD | -267.128% |
| Itoco Inc. | 919.14 Thousand USD | -15631.72% |
| Rasna Therapeutics, Inc. | 4.23 Million USD | -3311.583% |
| Pathfinder Cell Therapy, Inc. | 1.11 Million USD | -12821.984% |
| Mobile Lads Corp. | 554.54 Thousand USD | -25974.843% |
| CytoDyn Inc. | 18.05 Million USD | -700.737% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 25.16 Thousand USD | -574404.351% |
| NanoSphere Health Sciences Inc. | 220.07 Thousand USD | -65602.615% |
| Alseres Pharmaceuticals, Inc. | 1.41 Million USD | -10084.379% |
| SYBLEU INC | 160.87 Thousand USD | -89781.026% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 1.81 Million USD | -7860.987% |
| International Stem Cell Corporation | 5.27 Million USD | -2643.256% |
| Bioxytran, Inc. | 3.82 Million USD | -3685.116% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 52.64 Thousand USD | -274579.913% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 20.34 Thousand USD | -710694.868% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 36.26 Million USD | -298.712% |
| Adhera Therapeutics, Inc. | 1.61 Million USD | -8836.774% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 735.83 Thousand USD | -19550.737% |
| Innovation Pharmaceuticals Inc. | 3.11 Million USD | -4547.927% |
| Neutra Corp. | 243.82 Thousand USD | -59204.572% |
| Windtree Therapeutics, Inc. | 17.45 Million USD | -728.304% |
| Coeptis Therapeutics, Inc. | 20.48 Million USD | -605.699% |
| IXICO plc | 4.7 Million USD | -2971.957% |
| IntelGenx Technologies Corp. | 8.79 Million USD | -1543.708% |
| Gelesis Holdings, Inc. | 117.74 Million USD | -22.802% |
| CSL Limited | 3.89 Billion USD | 96.286% |
| Cellectis S.A. | 97.32 Million USD | -48.579% |